首页> 美国政府科技报告 >Development of Anti-VEGF Receptor/Flk-1 Immunoliposomes for Cytotoxic Anti-Angiogenesis Therapy
【24h】

Development of Anti-VEGF Receptor/Flk-1 Immunoliposomes for Cytotoxic Anti-Angiogenesis Therapy

机译:用于细胞毒性抗血管生成疗法的抗VEGF受体/ Flk-1免疫脂质体的开发

获取原文

摘要

We hypothesized that tumor-associated endothelium can be targeted with chemotherapy-loaded immunoliposomes (ILs) directed against VEGF Receptor 2 (VEGFR2, F1K- 1, KDR). VEGFR2 is the primary receptor for VEGF-mediated tumor angiogenesis, and as a cell surface receptor on endothelial cells provides a highly accessible target for immunoliposome therapy. Accordingly, we have developed anti-VEGFR2 ILs to deliver highly potent chemotherapeutics to VEGFR2- expressing endothelial cells for cytotoxic antiangiogenic treatment. Cloned anti-VEGFR2 scFv 4G7 sequences were expressed in E. coli, and purified scFv containing a C-terminal cysteine residue were conjugated to liposomes using three different strategies.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号